United States Biotechnology & Medical Research

Flexion Therapeutics Inc (FLXN)

Track

Ticker: FLXN Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Muzikant Adam
Chief Business Officer
1 sale — total 12,062 USD
Sale 19 Jul 2021
Value US$357,713.90 | Price 384.45 | Shares 64,150
Sale 10 May 2021
Value US$2,085,829.81 | Price 209.61 | Shares 95,959
Sale 15 Mar 2021
Value US$53,336.00 | Price 11.80 | Shares 4,520
Sale 28 Jan 2021
Value US$32,931.20 | Price 12.55 | Shares 2,624
Planned sale 5 Jan 2021
Value US$76,006.77 | Price 11.13 | Shares 6,829
Planned sale 5 Jan 2021
Value US$76,006.77 | Price 11.13 | Shares 6,829
Sale 5 Jan 2021
Value US$67,592.49 | Price 11.13 | Shares 6,073
Sale 5 Jan 2021
Value US$44,575.65 | Price 11.13 | Shares 4,005
Sale 5 Jan 2021
Value US$76,006.77 | Price 11.13 | Shares 6,829
Sale 5 Jan 2021
Value US$73,480.26 | Price 11.13 | Shares 6,602
Buy 26 May 2020
Value US$99,996.00 | Price 9.75 | Shares 10,256
Buy 26 May 2020
Value US$19,997.25 | Price 9.75 | Shares 2,051
Planned sale 7 May 2020
Value US$26,253.44 | Price 10.88 | Shares 2,413
Sale 3 Jan 2020
Value US$0.00 | Price 0.00 | Shares 3,724
Planned sale 3 Jan 2020
Value US$0.00 | Price 0.00 | Shares 3,724
Sale 3 Jan 2020
Value US$0.00 | Price 0.00 | Shares 3,095
Planned sale 3 Jan 2020
Value US$0.00 | Price 0.00 | Shares 3,724
Sale 3 Jan 2020
Value US$0.00 | Price 0.00 | Shares 3,851
Sale 3 Jan 2020
Value US$0.00 | Price 0.00 | Shares 3,533
Buy 8 Aug 2019
Value US$21,480.00 | Price 10.74 | Shares 2,000
Buy 8 Aug 2019
Value US$25,136.21 | Price 10.85 | Shares 2,317
Buy 31 May 2019
Value US$27,626.75 | Price 11.05 | Shares 2,500
Buy 23 May 2019
Value US$101,120.00 | Price 12.64 | Shares 8,000
Buy 13 May 2019
Value US$47,960.00 | Price 11.99 | Shares 4,000
Buy 10 May 2019
Value US$50,067.35 | Price 12.48 | Shares 4,012
Planned sale 8 May 2019
Value US$22,614.88 | Price 10.06 | Shares 2,248
Buy 12 Mar 2019
Value US$50,008.56 | Price 12.36 | Shares 4,046
Planned sale 3 Jan 2019
Value US$9,220.56 | Price 12.36 | Shares 746
Planned sale 3 Jan 2019
Value US$40,516.08 | Price 12.36 | Shares 3,278
Planned sale 3 Jan 2019
Value US$9,072.24 | Price 12.36 | Shares 734
Planned sale 3 Jan 2019
Value US$7,687.92 | Price 12.36 | Shares 622
Planned sale 3 Jan 2019
Value US$7,687.92 | Price 12.36 | Shares 622
Buy 9 Nov 2018
Value US$85,476.50 | Price 17.10 | Shares 5,000
Buy 9 Nov 2018
Value US$66,221.60 | Price 16.56 | Shares 4,000
Buy 9 Aug 2018
Value US$223,300.00 | Price 22.33 | Shares 10,000
Buy 9 Aug 2018
Value US$93,680.00 | Price 23.42 | Shares 4,000
Planned sale 3 Jul 2018
Value US$412,300.00 | Price 25.00 | Shares 16,492
Planned sale 2 Jul 2018
Value US$841,191.53 | Price 25.10 | Shares 33,508
Buy 21 Nov 2017
Value US$24,655.70 | Price 24.66 | Shares 1,000
Buy 21 Nov 2017
Value US$41,456.54 | Price 24.39 | Shares 1,700
Buy 8 Nov 2017
Value US$118,000.00 | Price 23.60 | Shares 5,000
Buy 5 Sep 2017
Value US$24,200.00 | Price 24.20 | Shares 1,000
Buy 1 Sep 2017
Value US$47,900.00 | Price 23.95 | Shares 2,000
Buy 1 Sep 2017
Value US$24,550.00 | Price 24.55 | Shares 1,000
Buy 31 Aug 2017
Value US$34,925.00 | Price 25.40 | Shares 1,375
Buy 16 Jun 2017
Value US$26,888.12 | Price 17.02 | Shares 1,580
Buy 5 Jun 2017
Value US$86,151.50 | Price 17.23 | Shares 5,000
Buy 5 Jun 2017
Value US$85,047.50 | Price 17.01 | Shares 5,000
Planned sale 15 May 2017
Value US$32,967.08 | Price 19.39 | Shares 1,700
Planned sale 15 May 2017
Value US$96,480.94 | Price 18.81 | Shares 5,130
Planned sale 17 Apr 2017
Value US$5,772.00 | Price 28.86 | Shares 200
Planned sale 17 Apr 2017
Value US$135,360.00 | Price 28.20 | Shares 4,800
Planned sale 23 Mar 2017
Value US$69,000.00 | Price 23.00 | Shares 3,000
Planned sale 17 Mar 2017
Value US$102,038.50 | Price 20.41 | Shares 5,000
Planned sale 28 Feb 2017
Value US$12,250.02 | Price 20.42 | Shares 600
Planned sale 28 Feb 2017
Value US$655,429.02 | Price 19.96 | Shares 32,834
Planned sale 24 Feb 2017
Value US$95,757.50 | Price 19.15 | Shares 5,000
Planned sale 20 Jan 2017
Value US$91,747.00 | Price 18.35 | Shares 5,000
Planned sale 21 Dec 2016
Value US$184,628.00 | Price 18.46 | Shares 10,000
Buy 1 Dec 2016
Value US$163,807.00 | Price 16.38 | Shares 10,000
Buy 23 Nov 2016
Value US$30,688.30 | Price 18.41 | Shares 1,667
Buy 22 Nov 2016
Value US$29,900.20 | Price 17.95 | Shares 1,666
Buy 21 Nov 2016
Value US$599,994.00 | Price 18.00 | Shares 33,333
Buy 21 Nov 2016
Value US$29,827.40 | Price 17.90 | Shares 1,666
Buy 21 Jun 2016
Value US$5,483.12 | Price 13.71 | Shares 400
Buy 21 Jun 2016
Value US$6,880.76 | Price 13.65 | Shares 504
Buy 21 Jun 2016
Value US$63,288.18 | Price 13.76 | Shares 4,600
Buy 21 Jun 2016
Value US$180,114.05 | Price 13.62 | Shares 13,222
Buy 20 Jun 2016
Value US$45,813.47 | Price 13.70 | Shares 3,343
Buy 20 Jun 2016
Value US$48,019.93 | Price 13.98 | Shares 3,435
Buy 14 Jun 2016
Value US$13,387.00 | Price 13.39 | Shares 1,000
Buy 8 Jun 2016
Value US$58,716.00 | Price 14.00 | Shares 4,194
Buy 8 Jun 2016
Value US$9,941,274.00 | Price 14.00 | Shares 710,091
Buy 8 Jun 2016
Value US$58,716.00 | Price 14.00 | Shares 4,194
Buy 8 Jun 2016
Value US$58,716.00 | Price 14.00 | Shares 4,194
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-07-20 2021-07-19 S Sale
Muzikant Adam

Chief Business Officer

Officer
64,150 -43.2%
384.45
US$357,714 		64,150 -43.2% 384.45 US$357,714
2021-05-12 2021-05-10 S Sale
1.4
Arkowitz David

Chief Financial Officer

Officer
95,959 +16.6%
209.61
US$2,085,830 		95,959 +16.6% 209.61 US$2,085,830
2021-03-16 2021-03-15 S Sale
Layman Melissa

Chief Commercial Officer

Officer
77,955 +43.7%
411.21
US$2,710,661 		77,955 +43.7% 411.21 US$2,710,661
2021-01-29 2021-01-28 S Sale
Layman Melissa

Chief Commercial Officer

Officer
2,624 -2.9%
12.55
US$32,931 		2,624 -2.9% 12.55 US$32,931
2021-01-07 2021-01-05 PlS Planned sale
KELLEY SCOTT

Chief Medical Officer

Officer
6,829 -5.7%
11.13
US$76,007 		6,829 -5.7% 11.13 US$76,007
2021-01-07 2021-01-05 PlS Planned sale
3.4
Wentworth Kerry

Chief Regulatory Officer

Officer
6,829 -5.7%
11.13
US$76,007 		6,829 -5.7% 11.13 US$76,007
2021-01-07 2021-01-05 S Sale
1.4
Arkowitz David

Chief Financial Officer

Officer
6,073 -3.9%
11.13
US$67,592 		6,073 -3.9% 11.13 US$67,592
2021-01-07 2021-01-05 S Sale
Muzikant Adam

Chief Business Officer

Officer
4,005 -5.2%
11.13
US$44,576 		4,005 -5.2% 11.13 US$44,576
2021-01-07 2021-01-05 S Sale
2.9
Levine Mark S.

General Counsel

Officer
6,829 -6.0%
11.13
US$76,007 		6,829 -6.0% 11.13 US$76,007
2021-01-07 2021-01-05 S Sale
Willwerth Christina

Chief Strategy Officer

Officer
6,602 -5.4%
11.13
US$73,480 		6,602 -5.4% 11.13 US$73,480
2020-05-27 2020-05-26 B Purchase
Clayman Michael D.

President and CEO

Executive Director
10,256 +3.0%
9.75
US$99,996 		10,256 +3.0% 9.75 US$99,996
2020-05-27 2020-05-26 B Purchase
3.2
Stejbach Mark
Non-Executive Director
2,051 +inf%
9.75
US$19,997 		2,051 +inf% 9.75 US$19,997
2020-05-11 2020-05-07 PlS Planned sale
1.4
Arkowitz David

Chief Financial Officer

Officer
2,413 -2.0%
10.88
US$26,253 		2,413 -2.0% 10.88 US$26,253
2020-01-07 2020-01-03 S Sale
KELLEY SCOTT

Chief Medical Officer
3,724
0.00
US$0 		3,724 0.00 US$0
2020-01-07 2020-01-03 PlS Planned sale
2.9
Levine Mark S.

General Counsel
3,724
0.00
US$0 		3,724 0.00 US$0
2020-01-07 2020-01-03 S Sale
1.4
Arkowitz David

Chief Financial Officer
3,095
0.00
US$0 		3,095 0.00 US$0
2020-01-07 2020-01-03 PlS Planned sale
3.4
Wentworth Kerry

Chief Regulatory Officer
3,724
0.00
US$0 		3,724 0.00 US$0
2020-01-07 2020-01-03 S Sale
Bodick Neil

Chief Scientific Officer
3,851
0.00
US$0 		3,851 0.00 US$0
2020-01-07 2020-01-03 S Sale
Willwerth Christina

Chief Strategy Officer
3,533
0.00
US$0 		3,533 0.00 US$0
2019-08-09 2019-08-08 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
2,000 +4.6%
10.74
US$21,480 		2,000 +4.6% 10.74 US$21,480
2019-08-08 2019-08-08 B Purchase Clayman Michael D.

President and CEO

Executive Director
2,317 +3.3%
10.85
US$25,136 		2,317 +3.3% 10.85 US$25,136
2019-06-03 2019-05-31 B Purchase
1.4
Arkowitz David

Chief Financial Officer
2,500 +2.9%
11.05
US$27,627 		2,500 +2.9% 11.05 US$27,627
2019-05-24 2019-05-23 B Purchase
2.6
MERRIFIELD C ANN
Non-Executive Director
8,000 +400.0%
12.64
US$101,120 		8,000 +400.0% 12.64 US$101,120
2019-05-15 2019-05-13 B Purchase
1.4
Arkowitz David

Chief Financial Officer

Officer
4,000 +4.8%
11.99
US$47,960 		4,000 +4.8% 11.99 US$47,960
2019-05-13 2019-05-10 B Purchase
Clayman Michael D.

President and CEO

Executive Director
4,012 +5.7%
12.48
US$50,067 		4,012 +5.7% 12.48 US$50,067
2019-05-09 2019-05-08 PlS Planned sale
1.4
Arkowitz David

Chief Financial Officer

Officer
2,248 -2.6%
10.06
US$22,615 		2,248 -2.6% 10.06 US$22,615
2019-03-13 2019-03-12 B Purchase
Clayman Michael D.

President and CEO

Executive Director
4,046 +6.1%
12.36
US$50,009 		4,046 +6.1% 12.36 US$50,009
2019-01-04 2019-01-03 PlS Planned sale
Bodick Neil

Chief Scientific Officer

Officer
746 -1.1%
12.36
US$9,221 		746 -1.1% 12.36 US$9,221
2019-01-04 2019-01-03 PlS Planned sale
Clayman Michael D.

President and CEO

Executive Director
3,278 -4.7%
12.36
US$40,516 		3,278 -4.7% 12.36 US$40,516
2019-01-04 2019-01-03 PlS Planned sale
2.9
Levine Mark S.

General Counsel

Officer
734 -7.5%
12.36
US$9,072 		734 -7.5% 12.36 US$9,072
2019-01-04 2019-01-03 PlS Planned sale
3.4
Wentworth Kerry

Chief Regulatory Officer

Officer
622 -5.3%
12.36
US$7,688 		622 -5.3% 12.36 US$7,688
2019-01-04 2019-01-03 PlS Planned sale
KELLEY SCOTT

Chief Medical Officer

Officer
622 -3.9%
12.36
US$7,688 		622 -3.9% 12.36 US$7,688
2018-11-13 2018-11-09 B Purchase Clayman Michael D.

President and CEO

Executive Director
5,000 +7.8%
17.10
US$85,476 		5,000 +7.8% 17.10 US$85,476
2018-11-13 2018-11-09 B Purchase Arkowitz David

Chief Financial Officer

Officer
4,000 +9.0%
16.56
US$66,222 		4,000 +9.0% 16.56 US$66,222
2018-08-10 2018-08-09 B Purchase Clayman Michael D.

President and CEO

Executive Director
10,000 +15.3%
22.33
US$223,300 		10,000 +15.3% 22.33 US$223,300
2018-08-10 2018-08-09 B Purchase Arkowitz David

Chief Financial Officer

Officer
4,000 +9.9%
23.42
US$93,680 		4,000 +9.9% 23.42 US$93,680
2018-07-03 2018-07-03 PlS Planned sale Bodick Neil

Chief Scientific Officer

Officer
16,492 -20.9%
25.00
US$412,300 		16,492 -20.9% 25.00 US$412,300
2018-07-03 2018-07-02 PlS Planned sale Bodick Neil

Chief Scientific Officer

Officer
33,508 -29.8%
25.10
US$841,192 		33,508 -29.8% 25.10 US$841,192
2017-11-22 2017-11-21 B Purchase Bodick Neil

Chief Scientific Officer
1,000 +inf%
24.66
US$24,656 		1,000 +inf% 24.66 US$24,656
2017-11-22 2017-11-21 B Purchase Bodick Neil

Chief Scientific Officer
1,700 +2.7%
24.39
US$41,457 		1,700 +2.7% 24.39 US$41,457
2017-11-09 2017-11-08 B Purchase Clayman Michael D.

President and CEO

Executive Director
5,000 +16.5%
23.60
US$118,000 		5,000 +16.5% 23.60 US$118,000
2017-09-15 2017-09-05 B Purchase Deniz Yamo

Chief Medical Officer
1,000 +12.5%
24.20
US$24,200 		1,000 +12.5% 24.20 US$24,200
2017-09-15 2017-09-01 B Purchase Deniz Yamo

Chief Medical Officer
2,000 +33.3%
23.95
US$47,900 		2,000 +33.3% 23.95 US$47,900
2017-09-15 2017-09-01 B Purchase Deniz Yamo

Chief Medical Officer
1,000 +20.0%
24.55
US$24,550 		1,000 +20.0% 24.55 US$24,550
2017-09-15 2017-08-31 B Purchase Deniz Yamo

Chief Medical Officer
1,375 +37.9%
25.40
US$34,925 		1,375 +37.9% 25.40 US$34,925
2017-06-20 2017-06-16 B Purchase Stejbach Mark
1,580 +inf%
17.02
US$26,888 		1,580 +inf% 17.02 US$26,888
2017-06-06 2017-06-05 B Purchase Clayman Michael D.

President and CEO

Executive Director
5,000 +33.0%
17.23
US$86,152 		5,000 +33.0% 17.23 US$86,152
2017-06-06 2017-06-05 B Purchase COLELLA SAMUEL D Large shareholder
5,000 +inf%
17.01
US$85,048 		5,000 +inf% 17.01 US$85,048
2017-05-17 2017-05-15 PlS Planned sale Bodick Neil

Chief Medical Officer

Officer
1,700 -4.2%
19.39
US$32,967 		1,700 -4.2% 19.39 US$32,967
2017-05-17 2017-05-15 PlS Planned sale Bodick Neil

Chief Medical Officer

Officer
5,130 -11.2%
18.81
US$96,481 		5,130 -11.2% 18.81 US$96,481
2017-04-18 2017-04-17 PlS Planned sale Bodick Neil

Chief Medical Officer
200 -0.4%
28.86
US$5,772 		200 -0.4% 28.86 US$5,772
2017-04-18 2017-04-17 PlS Planned sale Bodick Neil

Chief Medical Officer
4,800 -9.4%
28.20
US$135,360 		4,800 -9.4% 28.20 US$135,360
2017-03-24 2017-03-23 PlS Planned sale DRISCOLL FREDERICK W

Chief Financial Officer

Officer
3,000 -27.8%
23.00
US$69,000 		3,000 -27.8% 23.00 US$69,000
2017-03-20 2017-03-17 PlS Planned sale Bodick Neil

Chief Medical Officer
5,000 -8.9%
20.41
US$102,038 		5,000 -8.9% 20.41 US$102,038
2017-03-02 2017-02-28 PlS Planned sale DRISCOLL FREDERICK W

Chief Financial Officer

Officer
600 -7.2%
20.42
US$12,250 		600 -7.2% 20.42 US$12,250
2017-03-02 2017-02-28 PlS Planned sale DRISCOLL FREDERICK W

Chief Financial Officer

Officer
32,834 -79.7%
19.96
US$655,429 		32,834 -79.7% 19.96 US$655,429
2017-02-27 2017-02-24 PlS Planned sale Bodick Neil

Chief Medical Officer
5,000 -8.2%
19.15
US$95,758 		5,000 -8.2% 19.15 US$95,758
2017-01-23 2017-01-20 PlS Planned sale Bodick Neil

Chief Medical Officer
5,000 -7.6%
18.35
US$91,747 		5,000 -7.6% 18.35 US$91,747
2016-12-22 2016-12-21 PlS Planned sale Bodick Neil

Chief Medical Officer

Officer
10,000 -13.2%
18.46
US$184,628 		10,000 -13.2% 18.46 US$184,628
2016-12-05 2016-12-01 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
10,000 +30.0%
16.38
US$163,807 		10,000 +30.0% 16.38 US$163,807
2016-11-23 2016-11-23 B Purchase Clayman Michael D.

President and CEO

Executive Director
1,667 +5.7%
18.41
US$30,688 		1,667 +5.7% 18.41 US$30,688
2016-11-23 2016-11-22 B Purchase Clayman Michael D.

President and CEO

Executive Director
1,666 +6.1%
17.95
US$29,900 		1,666 +6.1% 17.95 US$29,900
2016-11-22 2016-11-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
33,333 +inf%
18.00
US$599,994 		33,333 +inf% 18.00 US$599,994
2016-11-22 2016-11-21 B Purchase Clayman Michael D.

President and CEO

Executive Director
1,666 +6.5%
17.90
US$29,827 		1,666 +6.5% 17.90 US$29,827
2016-06-22 2016-06-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
400 +1.6%
13.71
US$5,483 		400 +1.6% 13.71 US$5,483
2016-06-22 2016-06-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
504 +2.0%
13.65
US$6,881 		504 +2.0% 13.65 US$6,881
2016-06-22 2016-06-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
4,600 +23.0%
13.76
US$63,288 		4,600 +23.0% 13.76 US$63,288
2016-06-22 2016-06-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
13,222 +195.1%
13.62
US$180,114 		13,222 +195.1% 13.62 US$180,114
2016-06-22 2016-06-20 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
3,343 +97.3%
13.70
US$45,813 		3,343 +97.3% 13.70 US$45,813
2016-06-22 2016-06-20 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
3,435 +inf%
13.98
US$48,020 		3,435 +inf% 13.98 US$48,020
2016-06-16 2016-06-14 B Purchase MERRIFIELD C ANN Non-Executive Director
1,000 +100.0%
13.39
US$13,387 		1,000 +100.0% 13.39 US$13,387
2016-06-10 2016-06-08 B Purchase LUBASH BARBARA N Large shareholder
4,194 +25.3%
14.00
US$58,716 		4,194 +25.3% 14.00 US$58,716
2016-06-10 2016-06-08 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
4,194 +25.3%
14.00
US$58,716 		4,194 +25.3% 14.00 US$58,716
2016-06-10 2016-06-08 B Purchase Versant Ventures III, LLC Large shareholder
4,194 +25.3%
14.00
US$58,716 		4,194 +25.3% 14.00 US$58,716
2016-06-10 2016-06-08 B Purchase LUBASH BARBARA N Large shareholder
710,091 +25.3%
14.00
US$9,941,274 		710,091 +25.3% 14.00 US$9,941,274
Explore more

More insider trading research around Flexion Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America